This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks
Bamco, the advisory arm of Ron Baron's Baron Capital Group, opened a new position in Moderna (NASDAQ:MRNA) during the second quarter of 2026.
Harrow Inc. (HROW)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Opaleye Management James A. Silverman | 2,400,000 | $101,928,000 | -16% | 9.23% |
| 2. | Private Capital Management Gregg J. Powers | 1,598,770 | $67,899,762 | +3% | 5.98% |
| 3. | Deep Track Capital David Kroin | 969,000 | $41,153,430 | 0.6% | |
| 4. | BAMCO Inc. Ron Baron | 809,350 | $34,373,094 | 0.05% | |
| 5. | Divisadero Street Capital William Zolezzi | 439,155 | $18,650,913 | 0.42% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.07 | 1,000 | $31,070.00 | 1,000 | 2026-05-18 | Filing | |
| $31.00 | 1,000 | $31,000.00 | 1,000 | 2026-05-18 | Filing | |
| $30.20 | 10,000 | $302,000.00 | 2,996,130 | 2026-05-14 | Filing | |
| $29.90 | 3,500 | $104,650.00 | 814,679 | 2026-05-14 | Filing | |
| $9.97 | 20,000 | $199,400.00 | 3,815,000 | 2024-04-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.00 | 11,250 | $450,000.00 | 0 | 2026-08-14 | Filing | |
| $39.67 | 4,263 | $169,122.16 | 59,428 | 2026-03-04 | Filing | |
| $39.67 | 134,000 | $5,316,061.40 | 3,622,000 | 2026-03-04 | Filing | |
| $39.15 | 1,309 | $51,250.49 | 63,691 | 2026-03-03 | Filing | |
| $39.15 | 59,000 | $2,309,991.60 | 3,756,000 | 2026-03-03 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 81,473 | $2,509,368 | 0.11% | |
| 2. | 33,253 | $1,024,192 | 0.01% | |
| 3. | 23,304 | $717,763 | 0.01% | |
| 4. | 13,477 | $415,092 | 0.47% | |
| 5. | 13,229 | $407,453 | 0.01% |
News See All
Harrow (HROW): Strong Product Momentum Meets A Steep H2 Revenue Target
On August 10, Harrow Inc. (NASDAQ:HROW) walked investors through a first half that fell short and a back half that now has to make up the difference.
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
According to reports, on August 6, Harrow, Inc. (NASDAQ:HROW) announced a definitive agreement to acquire global rights to Tyrvaya nasal spray from Viatris Inc. (NASDAQ:VTRS) for up to $100 million.
GROW Small Cap Equity Fund Covered Its Position in Harrow (HROW) in Q1
Grow Funds, an investment Advisor, released its Q1 2026 investor letter for “GROW Small Cap Equity Long/Short Fund”. A copy of the letter can be downloaded here.
Is Harrow, Inc. (HROW) A Good Stock To Buy Now?
Is HROW a good stock to buy? We came across a bullish thesis on Harrow, Inc. on TopSecretStocks’s Substack by Simon. In this article, we will summarize the bulls’ thesis on HROW.
Top 10 Small Cap Stocks With Huge Growth Potential
In this article, we will discuss the Top 10 Small Cap Stocks With Huge Growth Potential.
Why B.Riley Reduced Harrow, Inc. (HROW) Price Target Despite Long-Term Optimism
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Harrow, Inc. (NASDAQ:HROW) is one of the best pharma stocks.
8 Best Small Cap Pharma Stocks to Buy Right Now
In this article, we will be taking a look at the 8 Best Small Cap Pharma Stocks to Buy Right Now.
Harrow Health, Inc. (NASDAQ:HROW) Q1 2026 Earnings Call Transcript
Harrow Health, Inc. (NASDAQ:HROW) Q1 2026 Earnings Call Transcript May 12, 2026 Operator: Good morning, and welcome to Harrow's First Quarter 2026 Earnings Conference Call.
Is Harrow, Inc. (HROW) A Good Stock To Buy Now?
Is HROW a good stock to buy? We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will summarize the bulls’ thesis on HROW.
Hedge Fund Resource Center